News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
7 Results
Type
Company Profile (1)
Press Release (6)
Section
Drug Development (1)
News (1)
Tag
Biotechnology (1)
Cancer (2)
Clinical research (4)
C-suite (1)
Data (4)
Events (4)
People (1)
Phase 1 (4)
Preclinical (1)
Date
Last 365 days (4)
2025 (4)
2024 (3)
Location
California (5)
Southern California (5)
United States (5)
7 Results for "genvivo".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
GenVivo to Present Phase 1 Trial Results for GEN2, A Personalizing Systemic Cancer Immunotherapy, at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10, 2025
·
6 min read
Press Releases
GenVivo Strengthens Oncology Leadership with Appointment of Noriyuki Kasahara, M.D., Ph.D., as Chief Scientific Officer
September 11, 2025
·
5 min read
Press Releases
GenVivo Highlights GEN-1013: A Novel Delivery of an IL-12 Immunotherapy at the 2025 American Association for Cancer Research (AACR) Annual Meeting
April 28, 2025
·
5 min read
Press Releases
GenVivo Highlights GEN2 Phase 1 Data and GEN-1013 Preclinical Data at the 2025 American Society of Gene + Cell Therapy (ASGCT) Annual Meeting
May 14, 2025
·
5 min read
Drug Development
GenVivo Announces Initiation of Patient Dosing in a US Phase I/Ib Clinical Trial Evaluating GEN2, a Personalizing, Gene Vector Immunotherapy, in Patients with Advanced Solid Tumors
GenVivo, Inc. announced that it has dosed the first US patient in a Phase I/Ib, open-label, dose-escalation and expansion clinical trial of GEN2.
June 27, 2024
·
5 min read
Press Releases
GenVivo to Present Phase 1 Trial Results for GEN2, A Personalizing Gene Vector Therapy, at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 11, 2024
·
5 min read
GenVivo, Inc.
